Bill > HB968

This bill designates certain compounds found in kratom, specifically mitragynine and 7-hydroxymitragynine (7-OH), and their synthetic or semi-synthetic derivatives, analogs, concentrations, and metabolites as controlled substances, placing them in Schedule I, which is the most restrictive category. It also revises definitions related to kratom products, clarifying that they are made from the plant's leaf and cannot be sold as pressed tablets or compressed pills, nor as multi-serving products. The bill mandates that kratom products sold in the state must be derived from kratom grown in the United States, and processors must have a registered agent in the state. Furthermore, it imposes strict labeling requirements, including the amount of mitragynine and 7-hydroxymitragynine per serving and total amount, along with warnings about consulting a physician and pharmacist, and stating that the product is not intended to diagnose, treat, cure, or prevent any disease. A real-time electronic logging system will be required for sales starting January 1, 2027, to track purchases and alert sellers of non-compliant products, with exceptions for imminent bodily harm, and law enforcement will have access to these records. The bill also prohibits advertising therapeutic benefits of kratom and marketing it to minors, with specific restrictions on advertising content and placement, and establishes penalties for violations, including significant fines and potential felony charges for processors and retailers who knowingly or with criminal negligence violate these provisions.

Justice

https://www.legis.ga.gov/legislation/72217